Health
Results: 9805-9816 of 10114

New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation to be presented at CTAD

KKR and Flerie Form Specialized Pharma Services Platform Frontier Biosolutions and Invest in Coriolis Pharma

UEG Week 2023 : Babies with a low birthweight four times more likely to develop fatty liver disease in later life






